Gong Ji Ryoun, Han Juhee, Lee Donghwan, Bae SeungJin
College of Pharmacy, Ewha Womans University, Seoul 03760, Korea.
Department of Statistics, Ewha Womans University, Seoul 03760, Korea.
Int J Environ Res Public Health. 2020 Dec 15;17(24):9412. doi: 10.3390/ijerph17249412.
To summarize utility estimates of breast cancer and to assess the relative impacts of study characteristics on predicting breast cancer utilities. We searched Medline, Embase, RISS, and KoreaMed from January 1996 to April 2019 to find literature reporting utilities for breast cancer. Thirty-five articles were identified, reporting 224 utilities. A hierarchical linear model was used to conduct a meta-regression that included disease stages, assessment methods, respondent type, age of the respondents, and scale bounds as explanatory variables. The utility for early and late-stage breast cancer, as estimated by using the time-tradeoff with the scales anchored by death to perfect health with non-patients, were 0.742 and 0.525, respectively. The severity of breast cancer, assessment method, and respondent type were significant predictors of utilities, but the age of the respondents and bounds of the scale were not. Patients who experienced the health states valued 0.142 higher than did non-patients ( <0.001). Besides the disease stage, the respondent type had the highest impact on breast cancer utility.
总结乳腺癌效用估计值，并评估研究特征对预测乳腺癌效用的相对影响。我们检索了1996年1月至2019年4月期间的Medline、Embase、RISS和KoreaMed数据库，以查找报告乳腺癌效用的文献。共识别出35篇文章，报告了224个效用值。使用分层线性模型进行元回归分析，将疾病阶段、评估方法、受访者类型、受访者年龄和量表范围作为解释变量。使用以死亡为锚点、从不患病到完美健康的量表进行时间权衡法估计，早期和晚期乳腺癌的效用分别为0.742和0.525。乳腺癌的严重程度、评估方法和受访者类型是效用的显著预测因素，但受访者年龄和量表范围不是。经历健康状态的患者比未患病者对健康状态的估值高0.142（<0.001）。除疾病阶段外，受访者类型对乳腺癌效用的影响最大。
